Methodological issues for using a common data model (CDM) of COVID-19 vaccine uptake and important adverse events of interest (AEIs): the Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) United Kingdom feasibility study

Gayathri Delanerolle, Robert Williams, Ana Stipancic, Rachel Byford, Anna Forbes, Sneha Anand, Declan Bradley, Ruby Tsang, Siobhán Murphy, Ashley Akbari, Stuart Bedston, Ronan Lyons, Rhiannon Owen, Jillian Beggs, Antony Chuter, Domnique Balharry, Mark Joy, Aziz Sheikh, F D Richard Hobbs, Simon de Lusignan

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) UK-wide collaboration was created to monitor vaccine uptake and effectiveness and provide pharmacovigilance using routine clinical and administrative data. To monitor these, pooled analyses may be needed. However, variation in terminologies present a barrier as England uses the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), while the rest of the United Kingdom uses the Read v2 terminology in primary care. The availability of data sources is not uniform across the United Kingdom.

OBJECTIVE: This study aims to use the concept mappings in the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) to identify common concepts recorded and to report these in a repeated cross-sectional study. We planned to do this for vaccine coverage and 2 adverse events of interest (AEIs), cerebral venous sinus thrombosis (CVST) and anaphylaxis. We identified concept mappings to SNOMED CT, Read v2, the World Health Organization's International Classification of Disease Tenth Revision (ICD-10) terminology, and the UK Dictionary of Medicines and Devices (dm+d).

METHODS: Exposures and outcomes of interest to DaC-VaP for pharmacovigilance studies were selected. Mappings of these variables to different terminologies used across the United Kingdom's devolved nations' health services were identified from the Observational Health Data Sciences and Informatics (OHDSI) Automated Terminology Harmonization, Extraction, and Normalization for Analytics (ATHENA) online browser. Lead analysts from each nation then confirmed or added to the mappings identified. These mappings were then used to report AEIs in a common format. We reported rates for windows of 0-2 and 3-28 days postvaccine every 28 days.

RESULTS: We listed the mappings between Read v2, SNOMED CT, ICD-10, and dm+d. For vaccine exposure, we found clear mapping from OMOP to our clinical terminologies, though dm+d had codes not listed by OMOP at the time of searching. We found a list of CVST and anaphylaxis codes. For CVST, we had to use a broader cerebral venous thrombosis conceptual approach to include Read v2. We identified 56 SNOMED CT codes, of which we selected 47 (84%), and 15 Read v2 codes. For anaphylaxis, our refined search identified 60 SNOMED CT codes and 9 Read v2 codes, of which we selected 10 (17%) and 4 (44%), respectively, to include in our repeated cross-sectional studies.

CONCLUSIONS: This approach enables the use of mappings to different terminologies within the OMOP CDM without the need to catalogue an entire database. However, Read v2 has less granular concepts than some terminologies, such as SNOMED CT. Additionally, the OMOP CDM cannot compensate for limitations in the clinical coding system. Neither Read v2 nor ICD-10 is sufficiently granular to enable CVST to be specifically flagged. Hence, any pooled analysis will have to be at the less specific level of cerebrovascular venous thrombosis. Overall, the mappings within this CDM are useful, and our method could be used for rapid collaborations where there are only a limited number of concepts to pool.

Original languageEnglish
Pages (from-to)e37821
JournalJMIR formative research
Volume6
Issue number8
DOIs
Publication statusPublished - 22 Aug 2022

Fingerprint

Dive into the research topics of 'Methodological issues for using a common data model (CDM) of COVID-19 vaccine uptake and important adverse events of interest (AEIs): the Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) United Kingdom feasibility study'. Together they form a unique fingerprint.

Cite this